Compare · LLY vs TYRA
LLY vs TYRA
Side-by-side comparison of Eli Lilly and Company (LLY) and Tyra Biosciences Inc. (TYRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and TYRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.06T, about 663.3x TYRA ($1.60B).
- Over the past year, LLY is up 49.9% and TYRA is up 82.0% - TYRA leads by 32.1 points.
- LLY has been more active in the news (12 items in the past 4 weeks vs 4 for TYRA).
- LLY has more recent analyst coverage (25 ratings vs 21 for TYRA).
- Company
- Eli Lilly and Company
- Tyra Biosciences Inc.
- Price
- $1125.22+0.14%
- $21.57-19.30%
- Market cap
- $1.06T
- $1.60B
- 1M return
- -8.61%
- -17.83%
- 1Y return
- +49.92%
- +82.03%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 4
- Recent ratings
- 25
- 21
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Tyra Biosciences Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest LLY
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
Latest TYRA
- SEC Form 8-K filed by Tyra Biosciences Inc.
- Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
- Tyra Biosciences to Present at the Cantor Global Healthcare Conference
- Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.
- SEC Form 424B5 filed by Tyra Biosciences Inc.
- SEC Form 10-Q filed by Tyra Biosciences Inc.
- Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
- Tyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits